CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma (NASDAQ: NVCT) reported Q3 2025 results and clinical updates on Nov 4, 2025. Key clinical milestones include initiation of the NXP900 Phase 1b single-agent study with combination dosing expected by year-end, completion of the Phase 1a dose-escalation showing robust pharmacodynamic responses, and a completed drug-drug interaction study supporting combination strategies. Poster presentations at the 2025 AACR-NCI-EORTC conference highlighted the emerging clinical profile and biomarker-based patient selection approach. Financially, cash and cash equivalents were $35.4M as of Sept 30, 2025, with a cash runway expected into 3Q-2027. Net loss was $7.5M in Q3 2025, up from $4.2M a year earlier.
Nuvectis Pharma (NASDAQ: NVCT) ha riportato i risultati del terzo trimestre 2025 e aggiornamenti clinici il 4 novembre 2025. I principali traguardi clinici includono l'inizio dello studio di Fase 1b NXP900 come agente singolo con dosing combinato previsto entro la fine dell'anno, il completamento della dose-escalation di Fase 1a che ha mostrato robuste risposte farmacodinamiche e uno studio di interazione farmaco-farmaco completato che supporta le strategie di combinazione. Le presentazioni poster alla conferenza AACR-NCI-EORTC 2025 hanno evidenziato il profilo clinico emergente e l'approccio di selezione dei pazienti basato su biomarcatori. Finanziariamente, la liquidità e equivalenti erano $35.4M al 30 settembre 2025, con una runway di cassa prevista fino al 3Q-2027. La perdita netta è stata $7.5M nel Q3 2025, in aumento rispetto ai $4.2M dell'anno precedente.
Nuvectis Pharma (NASDAQ: NVCT) informó resultados del tercer trimestre de 2025 y actualizaciones clínicas el 4 de noviembre de 2025. Los hitos clínicos clave incluyen el inicio del estudio de Fase 1b de NXP900 como agente único con dosificación combinada prevista para fin de año, la finalización de la fase 1a de escalado de dosis que mostró respuestas farmacodinámicas robustas y un estudio de interacción fármaco-fármaco completado que respalda estrategias de combinación. Presentaciones en cartel en la conferencia AACR-NCI-EORTC 2025 destacaron el perfil clínico emergente y el enfoque de selección de pacientes basado en biomarcadores. Financieramente, el efectivo y equivalentes eran $35.4M al 30 de septiembre de 2025, con una runway de efectivo prevista hasta el 3Q-2027. La pérdida neta fue de $7.5M en el Q3 2025, frente a $4.2M hace un año.
Nuvectis Pharma (NASDAQ: NVCT)는 2025년 11월 4일 2025년 3분기 실적 및 임상 업데이트를 발표했다. 주요 임상 이정표에는 NXP900의 1상 1b 시작 단일 제제로의 조합 투약이 연말까지 예상되며, 1상 1a 용량 증가의 완료로 강력한 약리학적 반응이 확인되었고, 조합 전략을 지원하는 약물 간 상호작용 연구가 완료되었다. 2025년 AACR-NCI-EORTC 컨퍼런스의 포스터 발표는 신흥 임상 프로필과 바이오마커 기반 환자 선발 접근 방식을 강조했다. 재무적으로 현금 및 현금성 자산은 2025년 9월 30일 기준 $35.4M였으며 현금 런웨이는 3Q-2027까지 예상된다. 3분기 순손실은 $7.5M으로, 작년 같은 기간의 $4.2M에서 증가했다.
Nuvectis Pharma (NASDAQ: NVCT) a publié les résultats du T3 2025 et les mises à jour cliniques le 4 novembre 2025. Les jalons cliniques clés incluent le démarrage de l’étude de phase 1b NXP900 en monothérapie avec une dose associée prévue d’ici la fin de l’année, l’achèvement de la phase 1a de montée en dose montrant des réponses pharmacodynamiques robustes et une étude d’interaction médicament-médicament terminée soutenant les stratégies de combinaison. Des présentations poster à la conférence AACR-NCI-EORTC 2025 ont mis en évidence le profil clinique émergent et l’approche de sélection des patients basée sur des biomarqueurs. Sur le plan financier, la trésorerie et les équivalents de trésorerie étaient de $35.4M au 30 septembre 2025, avec une runway de trésorerie prévue jusqu’au 3Q-2027. La perte nette était de $7.5M au T3 2025, en hausse par rapport à $4.2M il y a un an.
Nuvectis Pharma (NASDAQ: NVCT) berichtete am 4. November 2025 die Ergebnisse des Q3 2025 sowie klinische Updates. Wichtige klinische Meilensteine umfassen den Start der NXP900-Phase-1b-Studie als Einzelwirkstoff mit einer Kombinationstherapie, dosiert bis Ende des Jahres erwartet, den Abschluss der Phase-1a-Dosis-Eskalation, die robuste pharmakodynamische Reaktionen zeigte, und eine abgeschlossene Studie zu Wechselwirkungen zwischen Medikamenten, die Kombinationsstrategien unterstützt. Posterpräsentationen bei der AACR-NCI-EORTC-Konferenz 2025 hoben das aufkommende klinische Profil und den biomarkerbasierten Patientenselect-Ansatz hervor. Finanziell lagen Bargeld und Barmitteläquivalente am 30. September 2025 bei $35.4M, mit einer Cash-Runway voraussichtlich bis in das 3Q-2027. Der Nettobetriebsverlust betrug im Q3 2025 $7.5M, gegenüber $4.2M im Vorjahr.
Nuvectis Pharma (NASDAQ: NVCT) أعلنت عن نتائج الربع الثالث من عام 2025 وتحديثات سريرية في 4 نوفمبر 2025. تشمل المعالم السريرية الرئيسية بدء تجربة المرحلة 1b لـ NXP900 كدواء أحادي مع توقع جرعات الجمع حتى نهاية العام، إكمال تجربة التسوية للجرعة من المرحلة 1a التي أظهرت استجابات فارماكوديناميكية قوية، ودراسة تفاعل دواء-دواء مكتملة تدعم استراتيجيات الدمج. أبرزت عروض الملصقات في مؤتمر AACR-NCI-EORTC 2025 الملف السريري الناشئ ونهج اختيار المرضى القائم على المؤشرات الحيوية. ماليًا، كانت النقدية وما يعادلها $35.4M حتى تاريخ 30 سبتمبر 2025، مع مسار تمويل نقدي متوقع حتى 3Q-2027. بلغت الخسارة الصافية $7.5M في الربع الثالث من 2025، مقارنة بـ $4.2M قبل عام.
- NXP900 Phase 1b single-agent study initiated
- Phase 1a dose-escalation showed robust pharmacodynamic responses
- Drug-drug interaction study completed supporting combinations
- Cash and equivalents of $35.4M as of Sept 30, 2025
- Cash runway expected into 3Q-2027
- Net loss increased to $7.5M in Q3 2025 from $4.2M
- Research and development expense rose to $5.8M for Q3 2025
- One-time $2.0M milestone expense for NXP900 recognized
- $0.7M expense related to the clinical drug-drug interaction study
FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows:
- NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-end
- NXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosing
- NXP900 clinical drug-drug interaction study in healthy volunteers successfully completed supporting our strategy for combination therapy
- Poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics highlight the emerging clinical profile of NXP900 and provide further support for the biomarker-based patient selection strategy
- Cash runway expected to support the company’s operations into 3Q-2027
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter 2025 and provided an update on recent business progress.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “Our activity in the third quarter focused on advancing the clinical work required to support our ambitious Phase 1b program for NXP900, which recently commenced.” Mr. Bentsur continued, “Our goal for the Phase 1b program is to showcase NXP900's therapeutic potential, both as a single agent and in combination with certain market-leading therapies with the aim of reversing acquired resistance to these drugs. With the Phase 1b monotherapy component already underway, and the expected upcoming initiation of the combination component, we continue to make strides towards achieving this goal." Mr. Bentsur added, "To support and inform the Phase 1b program, we completed the NXP900 Phase 1a dose escalation study and the drug-drug interaction study in healthy volunteers and are pleased with NXP900’s emerging clinical profile, especially with the deep pharmacodynamic response observed at clinically relevant doses.” Mr. Bentsur concluded, “We believe that our cash position and focus on efficient operations will enable us to achieve the key milestones and potential value inflection points for the NXP900 Phase 1b program.”
Third Quarter 2025 Financial Results
Cash and cash equivalents were
The Company's net loss was
Research and development expenses, including non-cash stock-based compensation, were
General and administrative expenses, including non-cash stock-based compensation, were
Interest income was
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company's lead program, NXP900, is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study and is being evaluated in a Phase 1b program. The Company is also considering next steps for NXP800, an oral small molecule GCN2 activator that has demonstrated anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer. For additional information about Nuvectis Pharma please visit: https://nuvectis.com/
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate", "believe", "contemplate", "could", "estimate", "expect", "intend", "seek", "may", "might", "plan", "potential", "predict", "project", "target", "aim", "should", "will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations and interpretations of data and information available, including but not limited to preclinical and clinical data generated to date for NXP900, the timing and data expectations for the NXP900 Phase 1b program and estimates and projections regarding our financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Furthermore, certain forward-looking statements are based on assumptions regarding future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled "Risk Factors" in our Q2 2025 Form 10-Q and our other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer, and President
Media Relations Contact
Kevin Gardner
LifeSci Advisors
| NUVECTIS PHARMA, INC. BALANCE SHEET (USD in thousands, except per share and share amounts) | |||||||||||||||||
| September 30, | December 31, | ||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| Assets | |||||||||||||||||
| CURRENT ASSETS | |||||||||||||||||
| Cash and cash equivalents | $ | 35,442 | $ | 18,533 | |||||||||||||
| Other current assets | 145 | 74 | |||||||||||||||
| TOTAL CURRENT ASSETS | 35,587 | 18,607 | |||||||||||||||
| TOTAL ASSETS | $ | 35,587 | $ | 18,607 | |||||||||||||
| Liabilities and Shareholders’ Equity | |||||||||||||||||
| CURRENT LIABILITIES | |||||||||||||||||
| Accounts payables | $ | 6,439 | $ | 2,498 | |||||||||||||
| Payable offering costs | 75 | — | |||||||||||||||
| Accrued liabilities | 65 | 840 | |||||||||||||||
| Employee compensation and benefits | 4,998 | 5,556 | |||||||||||||||
| TOTAL CURRENT LIABILITIES | 11,577 | 8,894 | |||||||||||||||
| TOTAL LIABILITIES | 11,577 | 8,894 | |||||||||||||||
| COMMITMENTS AND CONTINGENCIES | |||||||||||||||||
| SHAREHOLDERS’ EQUITY | |||||||||||||||||
| Common Shares, | * | * | |||||||||||||||
| Additional paid in capital | 116,383 | 82,958 | |||||||||||||||
| Accumulated deficit | (92,373 | ) | (73,245 | ) | |||||||||||||
| TOTAL SHAREHOLDERS’ EQUITY | 24,010 | 9,713 | |||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 35,587 | $ | 18,607 | |||||||||||||
* Represents an amount lower than
| NUVECTIS PHARMA, INC. STATEMENT OF OPERATIONS (USD in thousands, except per share and share amounts) | ||||||||||||||||||
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||
| OPERATING EXPENSES | ||||||||||||||||||
| Research and development | $ | 5,774 | $ | 2,819 | $ | 13,067 | $ | 8,422 | ||||||||||
| General and administrative | 2,020 | 1,540 | 6,890 | 4,976 | ||||||||||||||
| OPERATING LOSS | (7,794 | ) | (4,359 | ) | (19,957 | ) | (13,398 | ) | ||||||||||
| Finance income | 332 | 206 | 829 | 646 | ||||||||||||||
| NET LOSS | $ | (7,462 | ) | $ | (4,153 | ) | $ | (19,128 | ) | $ | (12,752 | ) | ||||||
| EFFECT OF WARRANT MODIFICATION | (2,429 | ) | — | (2,429 | ) | — | ||||||||||||
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $ | (9,891 | ) | $ | (4,153 | ) | $ | (21,557 | ) | $ | (12,752 | ) | ||||||
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING | $ | (0.44 | ) | $ | (0.24 | ) | $ | (1.01 | ) | $ | (0.75 | ) | ||||||
| Basic and diluted weighted average number of common shares outstanding | 22,719,057 | 17,230,559 | 21,351,228 | 16,898,040 | ||||||||||||||
FAQ
What clinical milestone did Nuvectis (NVCT) announce on Nov 4, 2025?
How much cash did Nuvectis (NVCT) report on Sept 30, 2025 and how long is the runway?
Why did Nuvectis (NVCT) net loss increase in Q3 2025?
What clinical data supported NXP900’s development as of Nov 4, 2025?
Will Nuvectis (NVCT) pursue combination trials for NXP900 in 2025?
